Fluidigm, a US-based provider of integrated fluidic circuits for the life sciences market, plans to raise $80.2m at the upper end of its flotation range.
Fluidigm will offer 5.17 million common shares when it floats on the Nasdaq stock exchange at between $13.50 and $15.50 per share. Investment banks Deutsche Bank and Piper Jaffray are co-lead underwriters of the initial public offering (IPO) and can sell a further 775,862 shares if demand is strong enough.
The company originally filed for an IPO in early 2008, but canceled the offering later that same year and has reportedly raised more than $200m from investors.
In its regulatory filing, EuclidSR Partners, a corporate venturing joined venture including drugs company GlaxoSmithKline, has 6.6% and will be diluted to 4.8% after the IPO.
The Singapore government owns 13.7% pre-IPO, mutual fund manager Fidelity has 10.9%,while venture capital firms Versant Ventures, InterWest and Alloy Ventures own stakes. Lilly ventures, the corporate venturing unit of drugs company Eli Lilly, General Electric, Lehman Brothers, Piper Jaffray have also invested.